Cytosorbents Share Price Today
(NASDAQ: CTSO)

Name: Cytosorbents Share Price Today (NASDAQ: CTSO) - Cytosorbents Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Cytosorbents share price is $1.14 & ₹99.14 as on 6 Mar 2025, 2.30 'hrs' IST

$1.14

▲

0.14

(14%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Cytosorbents share price in Dollar and Rupees. Guide to invest in Cytosorbents stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Cytosorbents, along with analyst recommendations, forecasts, and comprehensive financials.

Cytosorbents share price movements

Today's Low: $1.00
Today's High: $1.14
$1.14
12.28%
Downside
Day's Volatility :12.48%
Upside
0.23%
52 Weeks Low: $0.70
52 Weeks High: $1.61
$1.14
38.6%
Downside
52 Weeks Volatility :56.52%
Upside
29.19%

Cytosorbents (CTSO) Returns

Period	Cytosorbents Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	8.11%	2.1%	0.0%
6 Months	-1.96%	-4.1%	0.0%
1 Year	2.04%	2.2%	0.0%
3 Years	-73.19%	11.8%	-11.6%

Cytosorbents (CTSO) Key Statistics

in dollars & INR

Previous Close	$1.0
Open	$1.0
Today's High	$1.1426
Today's Low	$1.0
Market Capitalization	$60.9M
Today's Volume	$6.4K
52 Week High	$1.61
52 Week Low	$0.7
Revenue TTM	$37.7M
EBITDA	$-19.7M
Earnings Per Share (EPS)	$-0.36
Profit Margin	-49.47%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-118.5%

How to invest in Cytosorbents Stock (CTSO) from India?

It is very easy for Indian residents to invest directly in Cytosorbents from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cytosorbents stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cytosorbents or CTSO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cytosorbents or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cytosorbents shares which would translate to 0.763 fractional shares of Cytosorbents as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Cytosorbents, in just a few clicks!

Returns in Cytosorbents (CTSO) for Indian investors in Rupees

The Cytosorbents stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Cytosorbents investment value today

Current value as on today

₹1,21,289

Returns

₹21,289

(+21.29%)

Returns from Cytosorbents Stock

₹16,327 (+16.33%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Cytosorbents (CTSO)

-67%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Cytosorbents Stock from India on INDmoney has decreased by -67% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Cytosorbents

Avenir Corporation
5.08%
Skylands Capital, LLC
4.57%
Vanguard Group Inc
3.20%
Neuberger Berman Group LLC
2.76%
Sargent Investment Group, LLC
2.05%
Granahan Investment Management Inc..
1.98%

Analyst Recommendation on Cytosorbents

Buy

77%Buy

22%Hold

0%Sell

Based on 9 Wall street analysts offering stock ratings for Cytosorbents(by analysts ranked 0 to 5 stars)

Based on 9 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Cytosorbents Stock (CTSO)

What analysts predicted

Upside of 338.6%

Target:

$5.00

Current:

$1.14

Insights on Cytosorbents Stock (Ticker Symbol: CTSO)

Price Movement
In the last 3 months, CTSO stock has moved up by 8.1%
Increasing Revenue
Revenue is up for the last 5 quarters, 7.75M → 8.61B (in $), with an average increase of 30.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -4.14M → -2.33B (in $), with an average decrease of 56236.2% per quarter
CTSO vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 54.6% return, outperforming this stock by 50.8%
CTSO vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 135.7% return, outperforming this stock by 209.9%
Price to Sales
ForCTSO every $1 of sales, investors are willing to pay $1.4, whereas for Boston Scientific Corp., the investors are paying $9.1 for every $1 of sales.

CTSO Cytosorbents Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$20.3M	↑ 51.34%
Net Income	$-17.2M	↑ 103.42%
Net Profit Margin	-84.98%	↓ 21.75%

	FY19	Y/Y Change
Revenue	$22.8M	↑ 12.41%
Net Income	$-19.3M	↑ 11.94%
Net Profit Margin	-84.63%	↑ 0.35%

	FY20	Y/Y Change
Revenue	$39.5M	↑ 73.3%
Net Income	$-7.8M	↓ 59.32%
Net Profit Margin	-19.86%	↑ 64.77%

	FY21	Y/Y Change
Revenue	$40.1M	↑ 1.66%
Net Income	$-24.6M	↑ 213.37%
Net Profit Margin	-61.23%	↓ 41.37%

	FY22	Y/Y Change
Revenue	$29.4M	↓ 26.8%
Net Income	$-32.8M	↑ 33.61%
Net Profit Margin	-111.76%	↓ 50.53%

	FY23	Y/Y Change
Revenue	$36.3M	↑ 23.81%
Net Income	$-28.5M	↓ 13.12%
Net Profit Margin	-78.43%	↑ 33.33%

	Q2 FY23	Q/Q Change
Revenue	$8.1M	↑ 2.05%
Net Income	$-6.2M	↓ 8.98%
Net Profit Margin	-76.22%	↑ 9.24%

	Q3 FY23	Q/Q Change
Revenue	$7.8M	↓ 3.94%
Net Income	$-9.2M	↑ 49.4%
Net Profit Margin	-118.56%	↓ 42.34%

	Q4 FY23	Q/Q Change
Revenue	$8.7M	↑ 11.79%
Net Income	$-5.8M	↓ 36.53%
Net Profit Margin	-67.31%	↑ 51.25%

	Q1 FY24	Q/Q Change
Revenue	$9.8M	↑ 12.9%
Net Income	$-6.4M	↑ 8.96%
Net Profit Margin	-64.97%	↑ 2.34%

	Q2 FY24	Q/Q Change
Revenue	$9.9M	↑ 1.11%
Net Income	$-4.1M	↓ 34.83%
Net Profit Margin	-41.87%	↑ 23.1%

	Q3 FY24	Q/Q Change
Revenue	$8.6B	↑ 86945.09%
Net Income	$-2.3B	↑ 56236.2%
Net Profit Margin	-27.1%	↑ 14.77%

	FY18	Y/Y Change
Profit	$12.8M	↑ 62.31%

	FY19	Y/Y Change
Profit	$15.4M	↑ 20.68%

	FY20	Y/Y Change
Profit	$28.4M	↑ 84.39%

	FY21	Y/Y Change
Profit	$29.1M	↑ 2.33%

	FY22	Y/Y Change
Profit	$15.4M	↓ 46.99%

	FY23	Y/Y Change
Profit	$22.4M	↑ 45.36%

	Q2 FY23	Q/Q Change
Profit	$4.7M	↑ 19.26%

	Q3 FY23	Q/Q Change
Profit	$4.6M	↓ 2.57%

	Q4 FY23	Q/Q Change
Profit	$5.3M	↑ 16.73%

	Q1 FY24	Q/Q Change
Profit	$6.6M	↑ 23.71%

	Q2 FY24	Q/Q Change
Profit	$6.5M	↓ 1.03%

	Q3 FY24	Q/Q Change
Profit	$8.6B	↑ 132285.74%

	FY18	Y/Y Change
Operating Cash Flow	$-10.8M	↑ 67.78%
Investing Cash Flow	$-1.5M	↓ 9.41%
Financing Cash Flow	$17.5M	↓ 13.2%

	FY19	Y/Y Change
Operating Cash Flow	$-16.8M	↑ 54.61%
Investing Cash Flow	$-1.5M	↓ 0.01%
Financing Cash Flow	$8.2M	↓ 53.18%

	FY20	Y/Y Change
Operating Cash Flow	$-5.6M	↓ 66.51%
Investing Cash Flow	$-1.7M	↑ 10.27%
Financing Cash Flow	$66.3M	↑ 711.33%

	FY21	Y/Y Change
Operating Cash Flow	$-14.0M	↑ 149.51%
Investing Cash Flow	$-4.3M	↑ 155.41%
Financing Cash Flow	$715.2K	↓ 98.92%

	FY22	Y/Y Change
Operating Cash Flow	$-28.2M	↑ 101.59%
Investing Cash Flow	$-6.5M	↑ 50.79%
Financing Cash Flow	$5.0M	↑ 593.46%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-6.9M	↑ 123.06%
Investing Cash Flow	$140.3K	↓ 120.54%
Financing Cash Flow	$931.1K	↑ 36.07%

Cytosorbents Technicals Summary

Sell

Neutral

Buy

Cytosorbents is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Cytosorbents (CTSO) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cytosorbents Corp	0.0%	-1.96%	2.04%	-73.19%	-83.84%
Medtronic Plc	2.26%	4.07%	8.74%	-12.76%	0.68%
Edwards Lifesciences Corp.	0.07%	8.12%	-19.19%	-34.12%	12.08%
Boston Scientific Corp.	0.07%	27.33%	53.68%	143.5%	203.93%
Stryker Corporation	-0.63%	8.92%	9.84%	53.87%	125.87%
Abbott Laboratories	7.11%	21.64%	15.28%	15.75%	78.63%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cytosorbents Corp	NA	NA	0.0	0.0	-1.18	-0.28	NA	0.24
Medtronic Plc	28.75	28.75	1.87	5.45	0.08	0.05	0.03	38.49
Edwards Lifesciences Corp.	30.5	30.5	5.57	2.45	0.17	0.08	NA	16.99
Boston Scientific Corp.	83.9	83.9	1.85	2.86	0.09	0.05	NA	14.76
Stryker Corporation	50.89	50.89	2.85	13.49	0.15	0.07	0.01	54.1
Abbott Laboratories	18.34	18.34	2.52	5.15	0.31	0.06	0.02	27.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cytosorbents Corp	Buy	$60.9M	-83.84%	NA	-49.47%
Medtronic Plc	Buy	$120.9B	0.68%	28.75	12.83%
Edwards Lifesciences Corp.	Buy	$42.0B	12.08%	30.5	76.75%
Boston Scientific Corp.	Buy	$154.8B	203.93%	83.9	11.07%
Stryker Corporation	Buy	$150.7B	125.87%	50.89	13.25%
Abbott Laboratories	Buy	$238.6B	78.63%	18.34	31.95%

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Organization	Cytosorbents
Employees	186
CEO	Dr. Phillip P. Chan M.D., Ph.D.
Industry	Health Technology

Management People of Cytosorbents

Name	Title
Dr. Phillip P. Chan M.D., Ph.D.	CEO & Director
Mr. Vincent J. Capponi M.S.	President & COO
Ms. Kathleen P. Bloch CPA, M.B.A.	Advisor
Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D.	Chief Medical Officer
Mr. Peter J. Mariani CPA	Chief Financial Officer
Dr. Christian Steiner M.D.	Executive Vice President of Sales & Marketing
Mr. Christopher Cramer M.B.A., M.S.	Senior Vice President of Business Development
Jodi Hoover	Executive
Dr. Robert H. Bartlett M.D.	Co-Chairman of Cardiac Surgery Advisory Board & Consultant

Important FAQs about investing in CTSO Stock from India :

What is Cytosorbents share price today?

Cytosorbents share price today stands at $1.14, Open: $1.00 ; Previous Close: $1.00 ; High: $1.14 ; Low: $1.00 ; 52 Week High: $1.61 ; 52 Week Low: $0.70.

The stock opens at $1.00, after a previous close of $1.00. The stock reached a daily high of $1.14 and a low of $1.00, with a 52-week high of $1.61 and a 52-week low of $0.70.

Can Indians buy Cytosorbents shares?

Yes, Indians can invest in the Cytosorbents (CTSO) from India.

With INDmoney, you can buy Cytosorbents at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Cytosorbents at zero transaction cost.

How can I buy Cytosorbents shares from India?

It is very easy to buy Cytosorbents from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cytosorbents (CTSO) be purchased?

Yes, you can buy fractional shares of Cytosorbents with INDmoney app.

What are the documents required to start investing in Cytosorbents stocks?

To start investing in Cytosorbents, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.